Peanut allergy is a life-threatening condition that affects approximately 3 million people in the United States. It is typically diagnosed early in life, and only 20% of children outgrow their allergy. Currently, there are no FDA approved methods of treatment, so those affected must avoid peanut products entirely and carry an epinephrine injection in case of an allergic reaction to prevent anaphylaxis. Peanut oral immunotherapy aims to treat peanut allergy by modulating the immune response through escalating the dosage of peanut protein over time, starting with the smallest dose, and steadily increasing the amount. Adverse side effects may occur from this method, including nausea, abdominal pain, upper respiratory reactions, and rashes.
This technology elicits a strong immune response with smaller dosages delivered by pollen grains, rather than traditional oral immunotherapy methods. It also offers longer-term therapeutic effects than conventional allergy shots or oral immunotherapy. This technology induces a higher protective immune response and suppresses the allergy-inducing response.
Reference Number: D-1374
Features, Benefits, & Advantages:
Treatment for peanut allergies
Alternative to existing allergy shots
Reduced side effects
Potential for low dose oral vaccines
A US provisional patent, serial number 62568846, was filed on 10/6/17.
Development Stage: A prototype has been developed and is being tested.
Harvinder Singh Gill, Chemical Engineering, Texas Tech University, Lubbock, Texas
Akhilesh Shakya, Chemical Engineering, Texas Tech University, Lubbock, Texas
Keywords: Peanut immunotherapy, allergy immunotherapy, drug delivery